TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

University of Helsinki

Status

Completed

Conditions

Diabetes Mellitus, Type 1

Treatments

Dietary Supplement: Nonhydrolysed infant formula

Dietary Supplement: Hydrolysed infant formula

Study type

Interventional

Funder types

Other

Industry

NIH

Identifiers

NCT00179777

U01HD040364 (U.S. NIH Grant/Contract)

MCT-49395

U01HD042444 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes. The TRIGR study was targeted at newborns who are at genetic risk for type 1 diabetes because their mother, father and/or full sibling has type 1 diabetes. All families were encouraged to breast feed their infants for as long as possible. Prior to birth, the child was randomly assigned to receive one of two infant formulas, should formula be required prior to 8 months of age. The study determined whether weaning to a possibly protective infant formula decreases these children's chances of developing diabetes - as it does in the animal models for diabetes.

Full description

The hypothesis for this study is that weaning to an extensively hydrolyzed infant formula will decrease the incidence of type 1 diabetes in subjects with risk-associated HLA genotypes and a first degree relative with type 1 diabetes, as it does in all relevant animal models for the disease.

Specific Aims:

I.a: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of diabetes-predictive auto-antibodies in subjects with risk-associated HLA genotype and a first degree relative with type 1 diabetes (mother, father and/or full sibling).

I-b: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of clinical diabetes in subjects with risk-associated HLA genotype and an affected first degree relative.

A secondary aim is to determine relationships between cow's milk antibodies, a measure of cow's milk exposure, and diabetes-associated auto-antibodies.

The mother of the unborn child is recruited during pregnancy. Randomization to one of two infant formulas takes place before birth (after 35 weeks gestation) or immediately after birth.

Experimental Arm: Use of extensively hydrolysed cow's milk based infant formula when needed in supplementation or substitution for breast milk through 6-8 months from birth.

Control Arm: Use of non-hydrolysed cow's milk based infant formula when needed in supplementation or substitution for breast milk through 6-8 months from birth.

All families were encouraged to breast feed their infants for as long as possible. The study infant formula was only used if exclusive breast feeding ceases before 8 months of age.

Cord blood for genotyping was obtained at birth, or failing that from a heel prick by 7 days of age. Only subjects with genotypes indicating increased genetic risk for type 1 diabetes remained in the intervention trial. All other subjects were withdrawn from the study.

All subjects were followed until the youngest subject turns age 10 years.

Enrollment

5,156 patients

Sex

All

Ages

Under 7 days old

Volunteers

No Healthy Volunteers

Inclusion criteria

Biological parent and/or full (not half) sibling of the newborn infant had type 1 diabetes as defined by the World Health Organization
The infant's parent or legal guardians gave signed consent to participate

Exclusion criteria

An older sibling of the newborn infant had been included in the TRIGR intervention
Multiple gestation
The parents were unwilling or unable to feed the infant cow's milk based products for any reason (e.g., religious, cultural).
The newborn infant had a recognizable severe illness such as those due to chromosomal abnormality, congenital malformation, respiratory failure needing assisted ventilation, enzyme deficiencies, etc.
The gestational age of the newborn infant was less than 35 weeks.
The infant was older than 7 days at randomization.
Inability of the family to take part in the study (e.g. the family has no access to any of the Study Centers, the family has no telephone).
The infant had received any infant formula other than Nutramigen prior to randomization.
No HLA sample drawn before the age of 8 days.